- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Ulcerative colitis Crohn's disease
- Meeting Date: November 2020
- Public Summary Document (PSD) November 2020 PBAC Meeting - (PDF 1597KB)
- Public Summary Document (PSD) November 2020 PBAC Meeting - (Word 127KB)
Vedolizumab – November 2020
Vedolizumab: Injection 108 mg in 0.68 mL pre-filled syringe, Injection 108 mg in 0.68 mL pre-filled pen; Entyvio®
Last updated
5 March 2021